This patient’s rapid response to osimertinib-crizotinib combination treatment in the setting of metastatic NSCLC leads us to recommend its usage in future cases of CEP85L-ROS1 fusion. This evidence concerns the gene CEP85L and non-small cell lung carcinoma.